Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
18 hedge funds and large institutions have $973K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.
29% more funds holding
Funds holding: 14 → 18 (+4)
55% less capital invested
Capital invested by funds: $2.17M → $973K (-$1.2M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$17.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.2K |
| 3 |
E
Ergoteles
New York
|
+$11.6K |
| 4 |
SG
StoneX Group
New York
|
+$10.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$176K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$60.4K |
| 3 |
Renaissance Technologies
New York
|
-$56.5K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.82K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$228 |
VRPX Hedge Fund Activity: Q4 2022 in Review
18 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q4 2022, worth a combined $973K — down 55% from $2.17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VRPX positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Belpointe Asset Management, opening a new position worth an estimated $17.3K. The largest seller was Vanguard Group, cutting an estimated $176K.
- 18 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q4 2022, up from 14 in Q3 2022.
- Funds reported $973K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 55% quarter-over-quarter.
- 4 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 0 closed out, a net change of +4 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Belpointe Asset Management, an estimated $17.3K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was Vanguard Group, an estimated $176K sold.
Based on aggregated 13F filings for Q4 2022.